Mazars is committed to supporting the pharma and life sciences sector; helping companies to navigate disruption, embrace innovation and grow with confidence. That’s why we recently partnered with FT Live for their Global Pharma and Biotech Summit - bringing the industry together to explore the latest trends, share top expertise and drive growth.
We have seen first-hand how pharma and life sciences businesses are grappling with significant change and disruption across the industry. With new technologies transforming R&D, innovative new treatments reshaping healthcare and fresh regulatory pressure, there is no better time to collectively examine the challenges faced and consider the best pathways ahead.
At Mazars, our dedicated Pharma & Life Sciences team combines global experience and industry expertise. From six key international hubs in the UK, USA, Switzerland, France, Germany and Ireland, we work with some of the largest pharma and life sciences companies in the world. Our teams work closely with clients, providing tailored services that give assurance and help their businesses to thrive.
Nigel Layton, our Global Head of Pharma & Life Sciences and Head of Investigations, shared insights into the complex area of compliance, anti-bribery and corruption in the pharmaceutical industry, speaking alongside Jeremy Hertzog, Partner at Mischon de Reya, and Darren Dodd, Writer/Editor at FT.
Nigel and Jeremy shared first-hand accounts of investigations into corporate misconduct, bribery allegations and large-scale fraud, and offered valuable advice to organisations operating within the sector.
Watch Nigel's expertise as he discusses anti-bribery and corruption in the pharma sector with Tarifa Simpson, our Healthcare and Life Sciences Co-Lead here.
Subscribe to receive the latest sector insights
Register your details to receive the latest news and insights for the pharma and life sciences sector.
Sign up for insights